Medical technology company Stryker (NYSE:SYK) reported second-quarter revenue of $6.59 billion, a 9.4% year-on-year increase. The company met Wall Street's revenue expectations, which had been set at $6.57 billion, but fell short of its organic sales growth target. Non-GAAP earnings per share came in at $3.69, exceeding forecasts by 5.8%. Despite these solid numbers, the market reacted negatively, with investors expressing concern over ongoing supply chain bottlenecks.
Peripheral and Cyber Risks
Management highlighted ongoing backorders in Stryker's peripheral vascular segment as a key challenge. CEO Kevin Lobo acknowledged that the fallout from a mid-year cybersecurity incident is still impacting production. Despite strong demand for most product lines, the company experienced 'meaningful lost sales in the quarter.' Elevated backlogs are anticipated to return to normal by the end of the third quarter, but production is still recovering unevenly. CFO Preston Wells indicated that the company has narrowed its full-year guidance to a midpoint of $15.02 per share.
Geographically, Stryker showed robust performance in several key regions, including Australia, Germany, Canada, and emerging markets such as India and Brazil. The U.S. medical, trauma, and endoscopy divisions performed well, partially offsetting the weaker results from the vascular segment. Additionally, Stryker's Mako robotics line achieved a record number of installations in the second quarter, with the introduction of new products like the Mako RPS expanding its role in joint replacement procedures.
Despite these positive developments, Stryker's current market cap of $133.4 billion reflects lingering investor uncertainty. The stock declined after the earnings report, suggesting skepticism about how quickly the company can resolve its supply and cybersecurity challenges. Management remains optimistic, citing strong order levels and elevated backlogs as indicators of durable demand. However, ongoing production bottlenecks and the costs of remediation, especially in the peripheral vascular business, are viewed as major risks. Backorder normalization in this area is expected by the end of the third quarter.
Looking ahead, Stryker's guidance for the remainder of the year is cautiously optimistic. The company anticipates continued demand for capital equipment and a stable procedural environment, with second-half performance depending on a full ramp-up of production. The primary challenge for investors is whether Stryker can deliver on these expectations without further disruptions. At this point, the market remains closely watching as SYK works to stabilize its operations.